Skip to main content
SpringerLink
Log in

Intensified inhibition of renin-angiotensin system: A way to improve renal protection?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Several large, randomized, multicenter studies in diabetic and nondiabetic patients with chronic proteinuric nephropathies have clearly demonstrated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) are able to reduce urinary protein excretion and retard renal disease progression. However, the number of patients who reach end-stage renal failure is still considerable and there is a great need to identify therapies that can arrest evolution of kidney damage. Maximizing renin-angiotensin system (RAS) blockade through combined ACE inhibitor and ARB therapy has been shown to further increase antiproteinuric and nephroprotective effects of each drug class. However, in order to slow to the greatest extent progression of renal disease, the ideal therapeutic approach for patients with proteinuric nephropathies should be a multimodal strategy including dual RAS blockade, antialdosterone therapy, lipid-lowering agents, smoking cessation, and tight glucose control for diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001, 12:2753–2758.

    PubMed  CAS  Google Scholar 

  2. Jafar TII, Stark PC, Schmid CII, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med 2001, 135:73–87.

    PubMed  CAS  Google Scholar 

  3. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799–812.

    Article  PubMed  CAS  Google Scholar 

  4. Campbell R, Sangalli F, Perticucci E, et al.: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003, 63:1094–1103.

    Article  PubMed  CAS  Google Scholar 

  5. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitors in nondiabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003, 361:117–124.

    Article  PubMed  CAS  Google Scholar 

  6. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448.

    Article  PubMed  CAS  Google Scholar 

  7. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288.

    Article  PubMed  CAS  Google Scholar 

  8. Macconi D, Macconi D, Abbate M, et al.: Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 2006, 168:1073.

    Article  PubMed  CAS  Google Scholar 

  9. Rudnicki M, Eder S, Perco P, et al.: Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidey Int 2007, 71:325–335.

    Article  CAS  Google Scholar 

  10. Zoja C, Morigi M, Remuzzi G: Proteinuria and phenotypic change of proximal tubular cells. J Am Soc Nephrol 2003, 14:S36–S41.

    Article  PubMed  Google Scholar 

  11. Cameron JS, Turner DR, Ogg CS, et al.: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978, 10:213–218.

    PubMed  CAS  Google Scholar 

  12. Remuzzi G, Ruggenenti P, Perico N: Chronic renal disease: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002, 136:604–615.

    PubMed  CAS  Google Scholar 

  13. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  14. Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing micro-albuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.

    Article  PubMed  CAS  Google Scholar 

  15. Wilmer WA, Hebert LA, Lewis EJ, et al.: Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the captopril study. Am J Kidney Dis 1999, 3:308.

    Google Scholar 

  16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  17. Bjorck S, Mulec H, Johnsen SA, et al.: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304:339.

    PubMed  CAS  Google Scholar 

  18. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997, 349:1857.

    Article  Google Scholar 

  19. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.

    PubMed  CAS  Google Scholar 

  20. de Zeeuw D, Ramjit D, Zhang Z, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309–2320.

    Article  PubMed  Google Scholar 

  21. Tarver-Carr M, Brancati F, Eberhardt M, et al.: Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J Am Soc Nephrol 2000, 11:168A.

    Google Scholar 

  22. Hoy WE, Wang Z, VanBuynder P, et al.: The natural history of renal disease in Australian Aborigines. Part I. Changes in albuminuria and glomerular filtration rate over time. Kidney Int 2001, 60:243–248.

    Article  PubMed  CAS  Google Scholar 

  23. Iseki K, Kinjo K, Iseki C, et al.: Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004, 44:806–814.

    Article  PubMed  CAS  Google Scholar 

  24. Aros C, Remuzzi G: The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens 2002, 20:S45–S53.

    Article  CAS  Google Scholar 

  25. Shake JG, Brandt RC, Daniels BS: Angiotensin II induces actin polymerization within the glomerular filtration barrier: Possible role in the local regulation of ultrafiltration. J Am Soc Nephrol 1992, 3:568A.

    Google Scholar 

  26. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993–2000.

    Article  PubMed  CAS  Google Scholar 

  27. Rasoul S, Carretero OA, Peng H, et al.: Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004, 22:593–603.

    Article  PubMed  CAS  Google Scholar 

  28. Laverman GD, Remuzzi G, Ruggenenti P: ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol 2004, 15:S64–S70.

    Article  PubMed  CAS  Google Scholar 

  29. Komine N, Khang S, Wead LM, et al.: Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002, 39:159–164.

    PubMed  CAS  Google Scholar 

  30. Azizi M, Chatellier G, Guyene TT, et al.: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995, 92:825–834.

    PubMed  CAS  Google Scholar 

  31. Mulec H, Johnson SA, Wiklund O, et al.: Cholesterol: a renal risk factor in diabetic nephropathy. Am J Kidney Dis 1993, 26:196–201.

    Google Scholar 

  32. Keane WF: Lipids and the kidney. Kidney Int 1994, 46:910–920.

    Article  PubMed  CAS  Google Scholar 

  33. Samuelsson O, Mulec H, Knight-Gibson C, et al.: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997, 12:1908–1915.

    Article  PubMed  CAS  Google Scholar 

  34. Brouhard BH, Takamori H, Satoh S, et al.: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 1994, 8:436–440.

    Article  PubMed  CAS  Google Scholar 

  35. Oda H, Keane WF: Recent advances in statins and the kidney. Kidney Int 1999, 56:S2–S5.

    Article  Google Scholar 

  36. Lee SK, Jin SY, Han DC: Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993, 8:1338–1343.

    PubMed  CAS  Google Scholar 

  37. Zoja C, Corna D, Camozzi D, et al.: How to fully protect the kidney in a severe model of progressive nephropathy: a multi-drug approach. J Am Soc Nephrol 2002, 13:2898–2908.

    Article  PubMed  CAS  Google Scholar 

  38. Ruggenenti P Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001, 375:1601–1608.

    Article  Google Scholar 

  39. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64–68.

    Article  PubMed  CAS  Google Scholar 

  40. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001, 37:477–483.

    Article  PubMed  CAS  Google Scholar 

  41. Lijnen P, Staessen J, Fagard R, Amery A: Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982, 49:1561–1563.

    Article  PubMed  CAS  Google Scholar 

  42. Naruse M, Tanabe A, Sato A, et al.: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002, 40:28–33.

    Article  PubMed  CAS  Google Scholar 

  43. Duprez D, De Buyzere M, Rietzschel ER, Clement DL: Aldosterone and vascular damage. Curr Hypertens Rep 2000, 2:327–334.

    Article  PubMed  CAS  Google Scholar 

  44. Schjoedt KJ, Rossing K, Juhl TR, et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006, 70:536–542.

    PubMed  CAS  Google Scholar 

  45. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006, 1:256–262.

    Article  PubMed  CAS  Google Scholar 

  46. Delyani JA, Rocha R, Cook CS, et al.: Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001, 19:185–200.

    Article  PubMed  CAS  Google Scholar 

  47. Weber MA: Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement, Rev Cardiovasc Med 2007, 8:S1–S6.

    PubMed  Google Scholar 

  48. Takahashi H, Ichihara A, Kaneshiro Y, et al.: Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J Am Soc Nephrol 2007, 18:2054–2061.

    Article  PubMed  CAS  Google Scholar 

  49. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  50. Mann JF, Gerstein HC, Yi QL, et al.: Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003, 14:641–647.

    Article  PubMed  Google Scholar 

  51. Asselbergs FW, Diercks GF, Hillege HL, et al.: Effect of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110:2809–2816.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11-24125, Bergamo, Italy

    Paolo Cravedi

Authors
  1. Paolo Cravedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piero Ruggenenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Remuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Cravedi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cravedi, P., Ruggenenti, P. & Remuzzi, G. Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Science Inc 9, 430–436 (2007). https://doi.org/10.1007/s11906-007-0078-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0078-3

Keywords

Search

Navigation